Case Library / Phishing / Alkem Laboratories: Ascend Laboratories Impersonation BEC and Enzene Biosciences Email Compromise
Phishing Documented incident

Alkem Laboratories: Ascend Laboratories Impersonation BEC and Enzene Biosciences Email Compromise

Fraudsters impersonating an Ascend Laboratories executive convinced Alkem Laboratories to wire USD 6,161,336 (about Rs 51.30 crore) to a fraudulent US bank account under a bogus tax-refund pretext; Rs 222.7 million remains unrecovered, and a second, separate business email compromise hit Alkem's Enzene Biosciences US subsidiary roughly 18 months later.

Share:

Social Engineering Examples·13 sources

What happened

Alkem Laboratories, a major Indian pharmaceutical multinational, suffered two distinct, disclosed business email compromise incidents roughly 18 months apart. In the first, fraudsters impersonated an executive of Alkem's US subsidiary Ascend Laboratories LLC, exploiting knowledge of a real Rs 51.30 crore intercompany payment Ascend had just made to parent Alkem. Using a fabricated excess-tax pretext, they convinced Alkem to wire USD 6,161,336, about Rs 51.30 crore, by SWIFT to a fraudulent account at Fifth Third Bank in the US. Mumbai Police, as reported by Hindustan Times, place the fraudulent correspondence between 27 October and 17 November 2023. The scheme came apart when Alkem's finance department went to verify the transaction with the US counterparty and the real head of international operations denied having made any refund request.

Alkem's board resolved on 12 January 2024 to disclose the incident to BSE and NSE. The company booked approximately Rs 513.1 million as an exceptional item for the quarter ended 31 December 2023, describing it as a cyber security incident that compromised the business email IDs of certain employees at one of its subsidiaries. Rs 290.4 million was recovered in the quarter ended 31 March 2024, leaving an audited net exceptional loss of Rs 222.7 million. Separately, on 15 May 2025, Alkem disclosed that Enzene Biosciences Ltd's US subsidiary had suffered its own cybersecurity incident in which employees' business email accounts were compromised, again resulting in a fraudulent fund transfer; the quantum was described as under investigation and has never been published.

How it worked

Ascend Laboratories LLC, Alkem's New Jersey-based US subsidiary, made a legitimate Rs 51.30 crore payment to parent Alkem on 25 October 2023 for materials supplied between November 2022 and January 2023. Two days later, on 27 October 2023, Alkem's Mumbai-based manager of treasury operations received an email purporting to be from Ascend's head of international operations, claiming Ascend's bank had flagged that the payment would trigger exorbitant taxes running into millions of dollars, and asking Alkem to refund the sum to a new account so it could be re-sent correctly. Shortly afterwards a second email supplied the destination account details, at Fifth Third Bank in the US. Believing the correspondence genuine, Alkem wired USD 6,161,336, about Rs 51.30 crore, via SWIFT.

Who that second email came from is the point on which the sources split, and it matters. The two police-sourced reports closest to the FIR, the Free Press Journal and Lokmat Times, both say it purported to come from the company's own internal accounting manager. This file follows them, because they are the earliest accounts, the most proximate to the police complaint, and they agree with each other independently. On that reading the case is internal impersonation layered on counterparty impersonation, and the control that would have caught it has to reach inside Alkem's own finance function rather than only across to the counterparty. Hindustan Times, the more widely cited report, describes a single stream of correspondence from the impersonated Ascend executive and mentions no second sender at all. No source gives a date for the second email or for the wire itself; Hindustan Times gives only a correspondence window running from 27 October to 17 November 2023.

The scheme was built on real, non-public knowledge of an actual intercompany payment and impersonated a real, identifiable counterparty, not a generic cold lure.

The lure and the tell

The lure combined three elements: precise, non-public knowledge of a real intercompany payment made just two days earlier, lending immediate plausibility; impersonation of real, identifiable individuals rather than an anonymous sender, Ascend's head of international operations and, on the police account, Alkem's own accounting manager; and a bureaucratic, low-suspicion pretext, avoiding an exorbitant tax charge, that framed the fraudulent transfer as protecting the company's money rather than risking it.

The tell was not in the emails. It came when Alkem's finance department went to verify the transaction with the US counterparty through an independent channel, and the real head of international operations said he had made no such request. A subsequent internal investigation found the emails had come from a fake domain built to closely mimic the legitimate one, according to the Mumbai Police account. Alkem's own filing to the exchanges instead describes compromised business email IDs. Those are two different attacks with two different answers, and no source reconciles them.

Outcome

Rs 290.4 million of the wired funds was recovered in the quarter ended 31 March 2024 and disclosed in Alkem's audited results, leaving a net exceptional loss of Rs 222.7 million. That is a recovery of 56.6 percent. Lokmat Times dates the recovery to 15 March 2024 and credits assistance from US and Indian banking authorities; Hindustan Times reports that US police seized the money and it was refunded to the company. The police-sourced press figures for the same chain, Rs 51.30 crore wired, Rs 28.98 crore seized and Rs 22.31 crore net, are approximately right but do not quite close, being short by Rs 0.01 crore.

Alkem filed complaints with the Parsippany-Troy Hills Police Department and the FBI in the US, and Mumbai's Central Region Cyber Police Station registered an FIR against unidentified persons under IPC sections 419 (cheating by personation), 420 (cheating), 465, 467, 468 and 471 (forgery-related) and 34 (common intention), plus relevant IT Act provisions. No arrests are reported in the sources reviewed, and as of the February 2025 reporting, proceedings to recover the balance were still live. Alkem's filings say only that it employed independent external agencies; Lokmat Times reports those agencies as Alvarez & Marsal and PwC. Alkem stated the incident did not involve any fraudulent act by its own promoters, directors, key managerial personnel, senior management or any other employee, and disclosed the matter to BSE and NSE as a matter of governance even though it said the amount did not cross its own quantitative materiality thresholds.

Separately, on 15 May 2025 Alkem disclosed that Enzene Biosciences Ltd's US subsidiary had suffered a distinct incident in which employee business email accounts were compromised, resulting in a fraudulent fund transfer of undisclosed quantum. No figure has been published since. No Alkem result through the audited year ended 31 March 2026 records an exceptional item for it, which indicates a loss materially smaller than the Rs 513.1 million Ascend fraud rather than a comparable one.

Why it matters

This case is a well-documented, dual illustration of business email compromise risk in cross-border intercompany treasury operations at a large, publicly listed multinational: attackers weaponized real, non-public transaction context, an actual recent invoice payment, combined with impersonation of a real executive, to make a fraudulent refund request credible enough to defeat a trained treasury function.

It also shows the limits of a remediation commitment. Alkem had engaged Check Point Software Technologies in November 2023, during the fraud window itself, and in January 2024 the two issued a joint statement committing to extend the same security infrastructure across every Alkem subsidiary, domestic and international, with a particular focus on networks and email. A second email-compromise fund transfer nonetheless occurred at a different subsidiary sixteen months later. No source explains why, and no source says the Enzene subsidiary was outside that perimeter. The honest lesson is that a stated intention to extend controls group-wide is not evidence that they were extended, and a second incident at a different subsidiary is the kind of outcome that should prompt someone to ask for the coverage evidence rather than the commitment.

The case additionally illustrates that cross-border law-enforcement and banking cooperation can claw back a meaningful share of stolen funds, 56.6 percent here, when reported and acted on quickly, and it is a clean example of India's SEBI-driven listed-company cyber-incident disclosure regime in action via BSE and NSE filings.

Defenses

Controls this case argues for:

  • Independently sourced callback verification, using contact details held on file rather than any supplied in the suspect email, before honoring any change-of-bank-account or refund request. Because the police account places the payment-details email inside Alkem's own finance function, that verification has to cover internal senders as well as counterparties. A callback policy written only for external vendors would not have caught this step.
  • Heightened scrutiny of urgent requests to redirect funds that are tied to a real, recently completed payment. The plausibility came from the transaction being genuine.
  • Monitoring for newly registered lookalike vendor and executive domains, alongside SPF, DKIM and DMARC enforcement, and separately mailbox-compromise detection. Both families of control are needed here, because the police investigation attributes the emails to a fake domain while Alkem's filing describes compromised mailboxes, and neither control covers the other's scenario.
  • Dual-approval or maker-checker sign-off for cross-border SWIFT transfers above a threshold, with the second reviewer confirming any payee or account change independently.
  • Extending email and endpoint security tooling uniformly across every subsidiary. This is the gap Alkem and Check Point described in January 2024, when they said the subsidiary involved in the 2023 incident had been "operating independently outside the corporate systems, which at the time was not leveraging Check Point's security solutions". That statement is about the 2023 incident; it should not be read as a description of any later one.
  • Rapid law-enforcement and correspondent-bank engagement to freeze funds in the destination country before they are moved on, which is what produced the partial recovery here.
Sources
  • Outcome of Board Meeting 9 February 2024 (Q3 FY2023-24 filed results). Alkem Laboratories Ltd. (primary). Alkem's results as filed with BSE and NSE. Both the standalone and the consolidated notes state that "a cyber security incident which compromised business email IDs of certain employees at one of the subsidiaries resulted in a fraudulent transfer of funds of approximately Rs 513.1 Million", reported under exceptional items. The note appears in the standalone results as well as the consolidated ones, which is the basis for treating the parent, not the subsidiary, as the entity that lost the money.
  • Q3FY24 Results Press Release and Investor Presentation. Alkem Laboratories Ltd. (primary). The 9 February 2024 press release carrying the same Rs 513.1 million exceptional-item note.
  • Unaudited Financial Results for the quarter and nine months ended 31 December 2024, filed with BSE and NSE 7 February 2025. Alkem Laboratories Ltd., mirrored on Business Standard's exchange-announcement server. (secondary). States the recovery in full: "In the subsequent quarter ended 31 March 2024, the Company recovered Rs 290.4 Million out of the above amount and hence amount of Rs 222.7 Million was also disclosed under exceptional item for the year ended 31 March 2024."
  • FY2023-24 Annual Report, Management Discussion and Analysis and statutory disclosures. Alkem Laboratories Ltd. (primary). The FY2023-24 annual report, showing the Rs 1,214.9 million total exceptional item for the year of which the cyber incident is one component.
  • Outcome of Board Meeting 29 May 2025 (FY2024-25 audited results). Alkem Laboratories Ltd. (primary). Carries the FY2023-24 comparative breakdown of exceptional items, itemising "Net loss on account of a cyber security incident at one of the subsidiaries amounting to Rs 222.7 Million" and, for the quarter ended 31 March 2024, "recovery of loss on cyber security incident amounting to Rs 290.4 Million".
  • Q4 and FY26 Results Presentation, 28 May 2026. Alkem Laboratories Ltd. (primary). Enumerates every exceptional item for the audited year ended 31 March 2026: Rs 1,130.6 million for the Labour Codes, Rs 747 million of real-estate impairment, offset by a Rs 142.9 million gain on the Indore facility. Nothing for the Enzene incident, which is the basis for the statement that Alkem has never booked it.
  • Alkem Labs duped of Rs 22 cr by frauds pretending to be officials of its US arm. Hindustan Times, 6 February 2025 (secondary). Mumbai Police-sourced account. Supports the 25 October 2023 intercompany payment, the 27 October 2023 pretext email from the impersonated Ascend executive, a correspondence window running to 17 November 2023, the Rs 51.30 crore transferred, the Rs 28.98 crore seized and refunded, the Rs 22.31 crore net figure, and the IPC and IT Act charges. It names the deceived employee and the impersonated executive; neither is named here, because neither has been convicted of anything. It does not describe a second sender, a second email, a Rs 90 crore follow-up request, or SWIFT.
  • Mumbai: Leading Pharma Firm Duped Of Rs 22.31 Crore In Sophisticated Cyber Scam; Case Registered. Free Press Journal, 4 February 2025 (secondary). The earliest and most FIR-proximate account. Source for the second email purporting to come from the company's own internal accounting manager, the destination account at Fifth Third Bank, the USD 6,161,336 SWIFT transfer, the discovery through contacting the real head of international operations, the internal finding of a fake lookalike domain, and the complaints to the Parsippany-Troy Hills Police Department and the FBI.
  • Mumbai: Pharma Company Falls Victim to Rs 22.31 Crore Cyber Fraud; FIR Registered. Lokmat Times, 4 February 2025 (secondary). Independent account of the same FIR, corroborating the internal accounting manager, Fifth Third Bank, the USD 6,161,336 figure and the fake domain. Additionally dates the Rs 28.98 crore recovery to 15 March 2024, credits US and Indian banking authorities, states that proceedings to recover the balance were still under way, and names Alvarez & Marsal and PwC as the firms assisting.
  • Alkem Labs reports 'fraudulent transfer' of Rs 52 crore from cyber-security breach. Moneycontrol, 12 January 2024 (secondary). Quotes Alkem's 12 January 2024 exchange filing verbatim, including the materiality-threshold language and the statement that the incident did not arise from any act of its promoters, directors, key managerial personnel or employees. That filing is not separately reachable online, so it is cited here through the press. Also the source for the November 2023 Check Point engagement and the joint statement.
  • Alkem Lab Reports Rs52 Crore Loss Due to Cyber Security Incident. Moneylife, updated 15 January 2024 (secondary). Carries the Alkem and Check Point joint statement in full, including the description of the affected subsidiary as "operating independently outside the corporate systems, which at the time was not leveraging Check Point's security solutions" and the commitment to extend the same infrastructure across every subsidiary. Note the statement is about the 2023 Ascend incident and predates the Enzene incident by sixteen months.
  • Alkem reports cyber security incident at Enzene's US subsidiary. The Hindu BusinessLine, 16 May 2025 (secondary). Quotes Alkem's 15 May 2025 exchange filing verbatim. That filing is not separately reachable online, so it is cited here through the press.
  • Alkem Labs US arm hit by cyber fraud; financial loss under probe. CNBC TV18, 15 May 2025 (secondary). Same-day coverage of the Enzene disclosure, corroborating The Hindu BusinessLine on the filing's wording and the quantum being under investigation.
Cite this case

Social Engineering Examples. “Alkem Laboratories: Ascend Laboratories Impersonation BEC and Enzene Biosciences Email Compromise”. Accessed 3 November 2026. https://socialengineeringexamples.com/alkem-laboratories-ascend-enzene-bec-2023-2024

Attack Chain & Defense
1Reconnaissance and pretext development
What happened

attackers likely built their pretext around genuine, close-in-time knowledge of a real intercompany payment (the Rs 51.30 crore Ascend-to-Alkem transfer of 25 October 2023) and senior Ascend personnel, including the actual head of international operations; this level of detail is consistent with either a mailbox the attackers already had visibility into or targeted OSINT and social engineering against Ascend/Alkem staff and public corporate materials, though no source confirms exactly how this information was obtained.

The control that would have stopped it

non-public transaction and personnel detail can leak through a compromised mailbox, a compromised counterparty, or patient social engineering, and is very hard to fully deny an attacker at enterprise scale; the realistic control is limiting who can see sensitive payment and org-chart data internally and monitoring for signs of mailbox compromise, rather than assuming this information stays secret.

2Sender setup, which the sources dispute
What happened

Alkem told the stock exchanges that business email IDs of certain employees at one of its subsidiaries had been compromised, while the Mumbai Police investigation, as reported by the Free Press Journal and Lokmat Times, concluded the emails came from a fake domain built to closely mimic the legitimate one. Those describe different preparation and call for different controls, and no source reconciles them.

The control that would have stopped it

because the sources disagree on whether the emails came from compromised mailboxes or a lookalike domain, the defensible answer is to run both controls rather than pick one: strict email authentication (SPF, DKIM, DMARC) and monitoring for newly registered lookalike domains, alongside mailbox-security tooling that flags suspicious rule changes and anomalous sign-ins, applied consistently across every subsidiary rather than only at corporate headquarters.

3Initial pretext contact
What happened

on 27 October 2023, two days after the genuine payment, Alkem's manager of treasury operations received an email purporting to be from Ascend's head of international operations, warning that the payment would trigger exorbitant taxes running into millions of dollars and asking for the funds to be refunded to a new account, an urgency-plus-plausibility lure grounded in a real, recent transaction.

The control that would have stopped it

training staff to treat any urgent, bureaucratically framed request to redirect a payment, especially one tied to taxes or penalties, as requiring independent verification regardless of how routine or plausible it sounds, directly counters the psychological lever this stage relies on.

4Fraudulent payment-details delivery
What happened

shortly afterwards a second email supplied the destination account, at Fifth Third Bank in the US. The two police-sourced reports closest to the FIR say that email purported to come from Alkem's own internal accounting manager, which makes this internal impersonation layered on counterparty impersonation. No source dates this email; Hindustan Times gives only a correspondence window running to 17 November 2023.

The control that would have stopped it

mandatory callback verification through previously known, independently sourced contacts, never numbers or addresses taken from the suspect email itself, before accepting any change of bank account or refund destination. Because the police account places this email inside Alkem's own finance function, the callback has to cover internal senders as well as counterparties; a control aimed only at the external party would not have caught it.

5Social engineering of the recipient into authorizing the wire
What happened

relying on the credibility built in stages 1 through 4 and without an independent callback to the real counterparts, Alkem wired USD 6,161,336, about Rs 51.30 crore, via SWIFT to the fraudulent account.

The control that would have stopped it

dual-approval or maker-checker sign-off for cross-border wire transfers above a set threshold, requiring a second, independent reviewer to confirm any payee or account change before release, would have given the scheme a second chance to be caught before the money left Alkem's control.

6Fund receipt and attempted extraction (objective completion)
What happened

once the funds landed in the fraudulent US account, the attackers moved to disperse or launder them out, the point at which the scheme's financial objective was substantially achieved, before US law enforcement intervened and seized a portion of the money.

The control that would have stopped it

rapid engagement with law enforcement and the correspondent/receiving bank as soon as fraud is suspected, requesting an emergency SWIFT recall or account freeze, can claw back funds before they are fully laundered out; this is the control that produced Alkem's partial recovery of Rs 290.4 million in this case, though full recovery is never guaranteed once funds leave the origin account.

Quick Facts
Victim
Alkem Laboratories Ltd.
(Mumbai-headquartered multinational pharmaceutical company; NSE/BSE-listed) via its US subsidiary Ascend Laboratories LLC being impersonated, and separately via employee email compromise at its subsidiary Enzene Biosciences Ltd.'s US operation
Company
Alkem Laboratories Ltd.
Location
Mumbai, India (Alkem Laboratories parent, the entity that lost the money) and Parsippany-Troy Hills, New Jersey, US (Ascend Laboratories LLC, the impersonated subsidiary, and where Alkem filed its US police complaint).
The destination account was at Fifth Third Bank in the US; no source locates that account or the subsequent seizure geographically.
Date
27 October 2023 to 17 November 2023
(window of fraudulent correspondence per Mumbai Police, as reported by Hindustan Times; no source dates the wire itself); board resolved to disclose 12 January 2024; Rs 290.4 million recovered in the quarter ended 31 March 2024; separate Enzene Biosciences US subsidiary incident disclosed 15 May 2025
Impact
Ascend Laboratories impersonation case, audited figures first.
BasismeasuredExceptional item in Alkem results filed with BSE and NSE
Alkem disclosed a fraudulent transfer of approximately Rs 513.1 million as an exceptional item for the quarter ended 31 December 2023, recovered Rs 290.4 million in the quarter ended 31 March 2024, and disclosed the net Rs 222.7 million as an exceptional item for the year ended 31 March 2024 (measured, from Alkem results filed with BSE and NSE). Recovery was 56.6 percent of the amount wired. The wire itself was denominated in dollars: USD 6,161,336 (measured, the figure in the Mumbai Police FIR as reported by the Free Press Journal and Lokmat Times, 2025), an implied rate of about 83.3 rupees per dollar, consistent with November 2023. The police-sourced press set of Rs 51.30 crore wired, Rs 28.98 crore seized and refunded and Rs 22.31 crore net does not quite close: Rs 51.30 crore minus Rs 28.98 crore is Rs 22.32 crore, leaving the reported net short by Rs 0.01 crore. Separately, the Enzene Biosciences US subsidiary email-compromise incident (disclosed 15 May 2025) resulted in a fraudulent fund transfer of undisclosed quantum; Alkem said the amount was under investigation, has published no figure since, and no Alkem result through the audited year ended 31 March 2026 records an exceptional item for it.
Status
Documented incident
Case Type
Real-World Incident
Sector
Healthcare
Threat Actor
unknown
Explore more

Related Cases

Browse by what this case has in common with others in the library.